Literature DB >> 7258297

The chemotactic response of tumor cells. A model for cancer metastasis.

W C Lam, E J Delikatny, F W Orr, J Wass, J Varani, P A Ward.   

Abstract

Injection of a C5-derived chemotactic factor for tumor cells into the peritoneal cavities of Sprague-Dawley rats induced diffuse mesenteric metastasis following the intravenous injection of Walker carcinosarcoma cells. Intraperitoneal injections of culture medium, histamine, or of trypsin-treated albumin resulted in many fewer metastases. Intraperitoneal injections of the chemotactic factor, unlike histamine, did not alter mesenteric vasopermeability as measured by the exudation of Evans blue into the mesentery. In vitro, tumor cells responded to the chemotactic factor by demonstrating directed migration in the Boyden chamber, by volume changes, measurable in the Coulter counter, and by demonstrating an increased adherence to nylon fibers. These phenomena are similar to the behavior of neutrophils in the presence of their chemotactic factors. All the responses in vitro were markedly depressed by the addition of 2-deoxyglucose, while the cell swelling response was slightly enhanced by cytochalasin B (again similar to the responses of leukocytes). The data suggest that movement of tumor cells from the circulation may be under chemotactic influence in the manner similar to the responsiveness of neutrophils to leukotactic stimuli in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7258297      PMCID: PMC1903731     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  A unique complement derived chemotactic factor for tumor cells.

Authors:  A G Romualdez; P A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  Neutrophil aggregation and swelling induced by chemotactic agents.

Authors:  J T O'Flaherty; D L Kreutzer; P A Ward
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

3.  Studies on the mechanisms of invasion in cancer. II. In vivo effects of a factor chemotactic for cancer cells.

Authors:  T Ozaki; K Yoshida; K Ushijima; H Hayashi
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

4.  Do polymorphonuclear leukocytes play a role in passive cutaneous anaphylaxis of the guinea pig?

Authors:  N S Taichman; H Z Movat
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

5.  Inhibition of granulocyte adherence by ethanol, prednisone, and aspirin, measured with an assay system.

Authors:  R R MacGregor; P J Spagnuolo; A L Lentnek
Journal:  N Engl J Med       Date:  1974-09-26       Impact factor: 91.245

6.  Relationship between the C5 peptides chemotactic for leukocytes and tumor cells.

Authors:  A G Romualdez; P A Ward; T Torikata
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

7.  Trauma and the localization of tumor cells.

Authors:  B Fisher; E R Fisher; N Feduska
Journal:  Cancer       Date:  1967-01       Impact factor: 6.860

8.  Acute immunologic pulmonary alveolitis.

Authors:  K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

9.  Characterization of two different factors chemotactic for cancer cells from tumor tissue.

Authors:  K Ushijima; H Nishi; A Ishikura; H Hayashi
Journal:  Virchows Arch B Cell Pathol       Date:  1976-08-11

10.  Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates.

Authors:  R Snyderman; J K Phillips; S E Mergenhagen
Journal:  J Exp Med       Date:  1971-11-01       Impact factor: 14.307

View more
  21 in total

1.  Bacterial rheotaxis.

Authors:  Henry C Fu; Thomas R Powers; Roman Stocker
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

2.  A novel method for selection of invasive tumor cells: derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity.

Authors:  T Kalebic; J E Williams; J E Talmadge; C S Kao-Shan; B Kravitz; K Locklear; G P Siegal; L A Liotta; M E Sobel; P S Steeg
Journal:  Clin Exp Metastasis       Date:  1988 Jul-Aug       Impact factor: 5.150

Review 3.  [Importance of fibroblast chemotaxis in wound healing and tumor cell evasion].

Authors:  H Mensing
Journal:  Klin Wochenschr       Date:  1985-02-15

4.  Phorbol ester binding and phorbol ester-induced arachidonic acid metabolism in a highly responsive murine fibrosarcoma cell line and in a less-responsive variant.

Authors:  A C Batchev; B L Riser; E G Hellner; S E Fligiel; J Varani
Journal:  Clin Exp Metastasis       Date:  1986 Jan-Mar       Impact factor: 5.150

5.  Tumor cell autocrine motility factor.

Authors:  L A Liotta; R Mandler; G Murano; D A Katz; R K Gordon; P K Chiang; E Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

Review 6.  Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion.

Authors:  M E Stearns; M Stearns
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

Review 7.  The role of cell adhesion proteins--laminin and fibronectin--in the movement of malignant and metastatic cells.

Authors:  J B McCarthy; M L Basara; S L Palm; D F Sas; L T Furcht
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro.

Authors:  J B McCarthy; L T Furcht
Journal:  J Cell Biol       Date:  1984-04       Impact factor: 10.539

9.  Should i.m. injections be avoided during cancer chemotherapy?

Authors:  P Kellokumpu-Lehtinen; K O Söderström
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells.

Authors:  F W Orr; S Mokashi; J Delikatny
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.